# Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can

Source: https://onco.cc/trials/nct07718737/  
OnCo record `nct07718737` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of AMT-116 and ramucirumab in lung cancer, run by Multitude Therapeutics Inc., not yet recruiting.

## Summary

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy is a phase 2/3, randomised interventional study registered as NCT07718737 by Multitude Therapeutics Inc., with a registry enrolment figure of 512 participants, started 2026-08-28 and due to reach its primary completion in 2028-03-30. Interventions recorded: AMT-116; Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab). Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Number of Participants with Adverse Events as Assessed by CTCAE v6.0. Lung eligibility wording from the registry: "Diagnosed with non-squamous non-small cell lung cancer (NSCLC) confirmed by pathological or cytological tests". Sites: Australia, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07718737
- Phase: 2/3
- Setting: Open-Label, Global, Multicenter, Randomized, Phase 2/3 Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Sponsor: Multitude Therapeutics Inc.
- Enrolled: 512

## Sources

- ClinicalTrials.gov NCT07718737: https://clinicaltrials.gov/study/NCT07718737

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [AMT-116](https://onco.cc/drugs/amt-116/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/)
- companies: [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07718737.json